(The following press release from Boehringer Ingelheim was received by 
e-mail. It was not confirmed by the sender.) 
EX US & UK Medical Media Only 
Boehringer Ingelheim and Eli Lilly and Company announce acceptance of
European marketing authorisation application for investigational Type 2
Diabetes treatment empagliflozin*  
which can be accessed at:
All interested users with a web-enabled mobile phone, iPhone, Blackberry, PDA
or other mobile device now have fast access to selected, up-to-the-minute
information about Boehringer Ingelheim.
Just follow: 
Mit freundlichen Grüßen / Kind regards,
Ute E. Schmidt 
Boehringer Ingelheim GmbH
Launch + establ. Products CVM
Tel.: +49 (6132) 77-97296
Fax: +49 (6132) 77-6601 
Visit us...
<>  <<Picture (Device Independent
Bitmap)>>  <>  <<Picture (Device
Independent Bitmap)>>  <>  <<Picture (Device
Independent Bitmap)>>  <>  
<<Picture (Device Independent Bitmap)>>
<>  <<Picture (Device
Independent Bitmap)>> 
Boehringer Ingelheim GmbH, Unternehmensleitung: Prof. Dr. Dr. Andreas Barner
(Sprecher), Hubertus von Baumbach, Prof. Dr. Wolfram Carius, Engelbert Tjeenk
Willink; Vorsitzender des Aufsichtsrates: Christian Boehringer, Sitz:
Ingelheim am Rhein; Registergericht Mainz: HR B 21005 
Press spacebar to pause and continue. Press esc to stop.